The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
about
The Importance of Thrombin in Cerebral Injury and DiseaseAbsolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.Imaging of prehospital stroke therapeuticsImproving neurovascular outcomes with bilateral forepaw stimulation in a rat photothrombotic ischemic stroke modelAncillary approaches to plasminogen activators.Role of argatroban during neurointerventional procedures in patients with heparin induced thrombocytopenia.The management of filter-related caval thrombosis complicated by heparin-induced thrombocytopenia and thrombosis.Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection.Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteersAdvances in medical revascularisation treatments in acute ischemic stroke.Thrombin activity associated with neuronal damage during acute focal ischemiaTissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction.A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient.Combining antithrombotic and fibrinolytic agents: can it be done?Clinical and magnetic resonance imaging predictors of very early neurological response to intravenous thrombolysis in patients with middle cerebral artery occlusion.Pharmacological revascularization of acute ischaemic stroke: focus on challenges and novel strategies.Advances and challenges in treatment and prevention of ischemic stroke.Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications.Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).Treatment of acute stroke: an update.Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy.Stroke Treatment Academic Industry Roundtable: The Next Generation of Endovascular Trials.Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke.Improving Cerebral Blood Flow after Arterial Recanalization: A Novel Therapeutic Strategy in Stroke.When less is more (brain)-Comment on "Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage".Emergency and critical care management of acute ischaemic stroke.Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage.Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update.Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke
P2860
Q26772131-774B6C73-F4A3-490F-A7CB-0176C7412158Q26796474-BC80820F-DC60-44AF-8B27-902EC1FDF42AQ26797275-36B100B5-C2FF-4F5E-8244-8B908ED11377Q30407296-7AC76E00-7CE8-428C-A25C-422081177590Q31095961-61EAFC38-7137-462B-9631-7B01457A1DA5Q33410515-B169047A-1AB0-44A4-A8FF-B539F6C21E1DQ33427411-5B7B5896-F098-42C6-B0FB-716E25607BEFQ33594546-4C81F77C-61E4-4939-BC9B-64B3131C1164Q33693490-52AA0C94-D7A3-4CD4-B8B6-9AC6BD8C5257Q34459133-7B66ADC2-0ACA-4443-8DE2-5C1DFE6EDB76Q36058083-ECD6FA91-FE60-472F-9CFF-3752DA6CE810Q36842960-EEB531E5-78B0-4E8D-AA86-380A87A2A4F4Q37112747-64B8F2E8-37D4-4CE1-941A-B0EA0262E106Q37342895-499B13A2-3A14-4269-8E0E-507F45B93D94Q37457623-7A037BF3-0BC9-4947-BA49-83B312D323FCQ37997491-E400AACC-A42D-4A8A-BF53-ECD01F69501CQ38127644-4FF4CA38-49A5-4B0E-AC1D-FBD6934F980BQ38225341-7CC57769-ACDE-4360-BCF6-061E356A7FE4Q38376753-8903DC10-40E9-45E8-AD8C-C76E17F60C10Q38541197-3EBA4F58-B3E7-4F4B-B1FE-1CDAEC2EADADQ38790291-E1CE1D21-C993-4B8E-BD74-21F8B8885DC6Q38825181-499F8DCB-9801-40A8-8CDE-2345BAAEAEEEQ39452481-6BF241EB-E897-4A30-B2F8-6D79CAFF556EQ42279127-0CF00ECB-2733-499D-8DDD-DC5713991EC1Q47170593-C7404113-8AAD-4142-BD5D-0113E1C0DFFFQ47823288-71D214A2-07FD-447D-A24B-A77746115B3FQ48458092-B3E255C0-3D12-4876-8336-2AEFBB1B59C3Q48558308-CBD6434C-ED9D-463A-9131-40823A2692A9Q48940520-FD2A9C22-D596-403F-BEFA-52BA63E28664Q50053948-AC0534EF-94FB-4506-B0E1-FA356E5F1FA6Q57158511-9C6EEE03-AE90-4674-9767-5748121ECBBC
P2860
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The argatroban and tissue-type ...... sults of a pilot safety study.
@ast
The argatroban and tissue-type ...... sults of a pilot safety study.
@en
type
label
The argatroban and tissue-type ...... sults of a pilot safety study.
@ast
The argatroban and tissue-type ...... sults of a pilot safety study.
@en
prefLabel
The argatroban and tissue-type ...... sults of a pilot safety study.
@ast
The argatroban and tissue-type ...... sults of a pilot safety study.
@en
P2093
P2860
P1433
P1476
The argatroban and tissue-type ...... esults of a pilot safety study
@en
P2093
Andrew D Barreto
Andrew M Demchuk
April Sisson
Clotilde Balucani
Georgios Tsivgoulis
James C Grotta
Jessica Lee
Kristian Barlinn
Loren Shen
Mohammad H Rahbar
P2860
P304
P356
10.1161/STROKEAHA.111.625574
P407
P577
2012-01-05T00:00:00Z